Cancer is increasingly recognized as a threat to the health of people worldwide. Current estimates are that 70% of new cancer cases will be in low- and middle-income countries by 2020. Drivers of these statistics include increasing life spans due to overall health and reductions in childhood and adult mortality; increasing obesity; higher smoking rates; and, in Africa, increasing rates of cancer associated with the growing number of long-term survivors of HIV. These trends are likely to continue. Cancer mortality rates are also higher in resource-poor economies. The goal of the Program in Global Oncology (PiGO) is to develop a robust research program that allows in- country investigators to develop data-driven approaches to the prevention and treatment of cancers of relevance in their region, as well as to develop a robust research enterprise that leverages the resources and opportunities in these countries to increase our understanding of cancer, especially those that are rare in the developed world and common in the developing world. Research conducted outside the U.S. has elucidated novel cancer risk factors, described unique molecular signatures for common malignancies, and suggested potential new strategies for cancer prevention and treatment. PiGO leverages the resources of our Cancer Center to lead effective research outside the U.S. through four Specific Aims: 1) Leverage data systems, methods and visualization to support global surveillance of cancer; 2) Expand our studies of tumors from HIV- infected and non-HIV-infected individuals to determine how and whether these cancers differ, utilizing the human and physical infrastructure we have developed in Uganda, South Africa and select areas in China; 3) Further develop a robust multidisciplinary research program to discover novel infection-related cancers, with particular emphasis on HIV-infected individuals; and 4) Develop effective in-country guidelines to improve the detection, potential prevention and treatment of common cancers found in resource poor settings. PiGO has 35 members drawn from 3 schools and 18 departments of FHCRC, UW and Children's, and $4.5M in peer-reviewed funding (direct dollars) in fiscal year 2013, of which $2.6M (49%) is from NCI. The program also has $ 21.4M (cancer-relevant portion) from the Bill and Melinda Gates Foundation. Members have published 322 papers, of which 10% are intra-programmatic, 33% are intra-programmatic and 18% are inter- institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-44S3
Application #
9842500
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843
Miller, Chris P; Tsuchida, Connor; Zheng, Ying et al. (2018) A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. Neoplasia 20:610-620
Baker, K Scott; Syrjala, Karen L (2018) Long-term complications in adolescent and young adult leukemia survivors. Hematology Am Soc Hematol Educ Program 2018:146-153
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:

Showing the most recent 10 out of 1267 publications